(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Japan deploys the military to counter a surge in bear attacks - 2Step by step instructions to Guarantee Your Fender bender Legal counselor has Areas of strength for a Record
- 3Inconceivable Spots To Stargaze All over The Planet
- 4Man triggers smoke bomb during failed crypto robbery
- 5Tehran defends ship seizure as a legal action, but tensions continue in the Gulf
- Find Wonderful Stream Voyage Objections On the planet
- The most effective method to Pick the Right Teeth Substitution Choice for You
- Takeda's AI-crafted psoriasis pill succeeds in late-stage studies
- The most effective method to Really Adjust Hypothesis and Practice in Your Brain science Studies
- Brazilian cardinal orders a popular Catholic priest to go offline following right-wing attacks
- 6 Shades Brands For Seniors
- Becoming the best at Discussion: Individual Procedures
- Practice environmental safety in Style: Divulging Famous Electric Vehicle Brands
- 5 Most Expected Film Delivery
